588 related articles for article (PubMed ID: 27932800)
1. TIMPs: versatile extracellular regulators in cancer.
Jackson HW; Defamie V; Waterhouse P; Khokha R
Nat Rev Cancer; 2017 Jan; 17(1):38-53. PubMed ID: 27932800
[TBL] [Abstract][Full Text] [Related]
2. The role of TIMPs in regulation of extracellular matrix proteolysis.
Arpino V; Brock M; Gill SE
Matrix Biol; 2015; 44-46():247-54. PubMed ID: 25805621
[TBL] [Abstract][Full Text] [Related]
3. Complex roles of tissue inhibitors of metalloproteinases in cancer.
Jiang Y; Goldberg ID; Shi YE
Oncogene; 2002 Mar; 21(14):2245-52. PubMed ID: 11948407
[TBL] [Abstract][Full Text] [Related]
4. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis.
Cruz-Munoz W; Khokha R
Crit Rev Clin Lab Sci; 2008; 45(3):291-338. PubMed ID: 18568853
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
6. The Continuing Saga of Tissue Inhibitor of Metalloproteinase 2: Emerging Roles in Tissue Homeostasis and Cancer Progression.
Stetler-Stevenson WG
Am J Pathol; 2023 Oct; 193(10):1336-1352. PubMed ID: 37572947
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
8. Novel functions of TIMPs in cell signaling.
Chirco R; Liu XW; Jung KK; Kim HR
Cancer Metastasis Rev; 2006 Mar; 25(1):99-113. PubMed ID: 16680576
[TBL] [Abstract][Full Text] [Related]
9. Functional disparities within the TIMP family in cancer: hints from molecular divergence.
Eckfeld C; Häußler D; Schoeps B; Hermann CD; Krüger A
Cancer Metastasis Rev; 2019 Sep; 38(3):469-481. PubMed ID: 31529339
[TBL] [Abstract][Full Text] [Related]
10. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.
Basu R; Lee J; Morton JS; Takawale A; Fan D; Kandalam V; Wang X; Davidge ST; Kassiri Z
Cardiovasc Res; 2013 Jun; 98(3):360-71. PubMed ID: 23524300
[TBL] [Abstract][Full Text] [Related]
11. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
Wei S; Xie Z; Filenova E; Brew K
Biochemistry; 2003 Oct; 42(42):12200-7. PubMed ID: 14567681
[TBL] [Abstract][Full Text] [Related]
12. TIMPs as multifacial proteins.
Lambert E; Dassé E; Haye B; Petitfrère E
Crit Rev Oncol Hematol; 2004 Mar; 49(3):187-98. PubMed ID: 15036259
[TBL] [Abstract][Full Text] [Related]
13. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the distinct biological functions and potential therapeutic applications of TIMP2 in cancer.
Peeney D; Liu Y; Lazaroff C; Gurung S; Stetler-Stevenson WG
Carcinogenesis; 2022 Jun; 43(5):405-418. PubMed ID: 35436325
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma.
Han J; Jing Y; Han F; Sun P
BMC Neurol; 2021 Nov; 21(1):447. PubMed ID: 34781885
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
17. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
18. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
Gomez DE; Alonso DF; Yoshiji H; Thorgeirsson UP
Eur J Cell Biol; 1997 Oct; 74(2):111-22. PubMed ID: 9352216
[TBL] [Abstract][Full Text] [Related]
19. Expression of metalloproteinases 2 and 9 and tissue inhibitors 1 and 2 as predictors of lymph node metastases in oropharyngeal squamous cell carcinoma.
Burduk PK; Bodnar M; Sawicki P; Szylberg Ł; Wiśniewska E; Kaźmierczak W; Martyńska M; Marszałek A
Head Neck; 2015 Mar; 37(3):418-22. PubMed ID: 24436008
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
